Jazz Pharmaceuticals

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell JAZZ and other ETFs, options, and stocks.

About JAZZ

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio.

CEO

Bruce C. Cozadd

CEOBruce C. Cozadd

Employees

2,800

Employees2,800

Headquarters

Dublin, Dublin

HeadquartersDublin, Dublin

Founded

2005

Founded2005

Employees

2,800

Employees2,800

JAZZ Key Statistics

Market cap

7.42B

Market cap7.42B

Price-Earnings ratio

17.69

Price-Earnings ratio17.69

Dividend yield

—

Dividend yield—

Average volume

726.25K

Average volume726.25K

High today

$124.71

High today$124.71

Low today

$121.80

Low today$121.80

Open price

$123.73

Open price$123.73

Volume

260.83K

Volume260.83K

52 Week high

$134.17

52 Week high$134.17

52 Week low

$99.06

52 Week low$99.06

JAZZ News

TipRanks 6d

FDA grants accelerated approval to Jazz Pharmaceuticals’ Ziihera

The Food and Drug Administration granted accelerated approval to zanidatamab-hrii, or Ziihera from Jazz Pharmaceuticals (JAZZ), Inc., a bispecific HER2-directed...

TipRanks 7d

Jazz Pharmaceuticals announces FDA approval of Ziihera in BTC

Jazz Pharmaceuticals (JAZZ) “announced the U.S. Food and Drug Administration accelerated approval of Ziihera 50mg/mL for injection for intravenous use for the t...

Analyst ratings

81%

of 21 ratings

Buy

81%

Hold

19%

Sell